Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

With Merck's Keytruda on top of the world and setting the standard for PD-1/L1 lung cancer data, Roche and Bristol defended the programs for their competing Tecentriq and Opdivo during ASCO investor events.

Rear view of businessman with suitcase looking at sunset above city

Merck & Co. Inc.'s stunning success in first-line metastatic lung cancer trials of Keytruda at the American Society of Clinical Oncology (ASCO) annual meeting set a high efficacy bar with prescribers and left its PD-1/L1 inhibitor rivals Bristol-Myers Squibb Co. and Roche on the defense.

After presentations at the ASCO meeting, held June 1-5 in Chicago, Merck's Keytruda (pembrolizumab) emerged as the clear leader in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer